157 related articles for article (PubMed ID: 33545199)
1. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
2. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
3. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Adel RM; Lotfy RA; Darwish AS; Amer AS
J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox and vitamin D
Ghaith MM; El-Boshy M; Almasmoum H; Abdelghany AH; Azzeh FS; Almaimani RA; Idris S; Ahmad J; Mahbub AA; BaSalamah MA; Elzubeir ME; Refaat B
J Trace Elem Med Biol; 2022 Dec; 74():127085. PubMed ID: 36179462
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H; Qin Y; Chen G; Zhao Y
Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
[TBL] [Abstract][Full Text] [Related]
6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.
Thephinlap C; Phisalaphong C; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2009 Sep; 5(5):474-82. PubMed ID: 19534681
[TBL] [Abstract][Full Text] [Related]
8. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.
Adel N; Mantawy EM; El-Sherbiny DA; El-Demerdash E
Toxicol Appl Pharmacol; 2019 Nov; 382():114748. PubMed ID: 31499193
[TBL] [Abstract][Full Text] [Related]
10. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Di Veroli A; Campagna A; De Muro M; Maurillo L; Trawinska MM; LeonettiCrescenzi S; Petriccione L; Romano A; D'Addosio A; Cenfra A; Montanaro M; Felici S; Andriani A; Carmosino I; Niscola P; Montefusco E; Breccia M; Latagliata R
Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
[TBL] [Abstract][Full Text] [Related]
12. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone.
Timoshnikov VA; Kichigina LA; Selyutina OY; Polyakov NE; Kontoghiorghes GJ
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443652
[TBL] [Abstract][Full Text] [Related]
16. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
19. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Huang WF; Chou HC; Tsai YW; Hsiao FY
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
[TBL] [Abstract][Full Text] [Related]
20. Desferrioxamine-induced alterations in hepatic iron distribution, DNA damage and lipid peroxidation in control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats.
Wahba ZZ; Murray WJ; Stohs SJ
J Appl Toxicol; 1990 Apr; 10(2):119-24. PubMed ID: 2362077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
